Saito et al. developed the p14 MIS peptide, a combination of the p14ARF mitochondrial targeting protein and CTSB proteolytic cleavage site, and used it as treatment in vitro in pancreas adenocarcinoma, uterine squamous cell carcinoma, lung adenocarcinoma, breast adenocarcinoma, colon adenocarcinoma, and hepatocellular carcinoma cell lines, but also in vivo, in a xenograft mouse model. Here, CTSB is linked to hepatocellular carcinoma.